BLPH Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 5.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Bellerophon Therapeutics Share Price & Price History
Current Price: $0.01
Price Change: +0.30 (1.20%)
As of 12/18/2024 01:00 AM ET
Bellerophon Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/13/2023 | Puissance Capital Management L | Major Shareholder | Sell | 1,076,841 | $0.10 | $107,684.10 | |  |
| 6/7/2023 | Life Science Opportu Puissance | Major Shareholder | Sell | 134,421 | $0.83 | $111,569.43 | 1,076,841 | |
| 5/18/2023 | Bobae Kim | VP | Sell | 9,455 | $10.00 | $94,550.00 | 1,723 | |
| 5/18/2023 | Life Science Opportu Puissance | Major Shareholder | Sell | 560,000 | $9.46 | $5,297,600.00 | 1,211,262 | |
Bellerophon Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 8/7/2023 | Acadian Asset Management LLC | 265,253 | $0.18M | 0.0% | N/A | 2.538% |  |
| 11/17/2022 | Telemetry Investments L.L.C. | 47,500 | $52K | 0.1% | -31.2% | 0.497% | |
| 7/26/2022 | Sepio Capital LP | 23,800 | $29K | 0.0% | N/A | 0.249% | |
| 11/16/2021 | Telemetry Investments L.L.C. | 85,500 | $0.35M | 0.5% | -6.0% | 0.899% | |
| 11/12/2021 | Renaissance Technologies LLC | 201,706 | $0.82M | 0.0% | -21.5% | 2.122% | |
| 11/9/2021 | BlackRock Inc. | 120,620 | $0.49M | 0.0% | +3.6% | 1.268% | |
Data available starting January 2016
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Read More on Bellerophon Therapeutics
Volume
7,027 shs
Average Volume
18,907 shs
Market Capitalization
$146.80 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.74
